The term TNBC was first used in 2005 (ref. 10) to refer to a subset of breast cancer patients for whom chemotherapy was the only treatment available, given that patients with TN disease lack ER, PR, and HER2 and, therefore, are not eligible to receive hormonal therapy or anti-HER2 agents. Here, PGR is linked to breast carcinoma.